Hepatitis C News

The FDA recently approved safety and efficacy revisions to the Mavyret label based on data from a hepatitis C/HIV-1 collection study and a liver and renal transplant study.

Patients who were negative for hepatitis C virus and received HCV-infected kidneys and antiviral treatment were clear of the disease and experienced good renal function up to a year after transplantation, according to study results recently published in the Annals of Internal Medicine.

Patients without hepatitis C who underwent heart transplantation with an HCV-positive organ were likely to develop HCV viremia posttransplant, but had high rates of sustained virologic response following direct-acting antiviral therapy, according to published results of a recent prospective study.

The American Legion, in partnership with AbbVie, announced the launch of its “Take on Hep C” nationwide initiative designed to provide free hepatitis C antibody testing to veterans and their communities, according to a press release.

“Test. Treat. Hepatitis.” is this year’s World Hepatitis Day theme. The direct-acting antiviral era has seen a significant increase in the number of patients with hepatitis C clearing their infection. Along with this, public awareness of the disease and its highly effective cure has increased.

Growing evidence supports the overall benefits and cost-effective outcomes of testing for and treating hepatitis C in the prison “microenvironment,” according to a review of recent studies.

SeraCare Life Sciences announced the launch of the company’s proprietary AccuSpan HCV RNA Linearity Panel designed to monitor HCV RNA recovery at defined intervals, according to a press release.

Results of a recent study provided continued confirmation that increased rates of hepatocellular carcinoma among patients treated with direct-acting antivirals compared with interferon correlated with patient characteristics such as age and liver function rather than treatment.

Researchers identified four patients with a novel hepatitis C genotype, according to study published in The Journal of Infectious Diseases.

Novel point-of-care hepatitis C tests have advanced the potential for same-day viral diagnosis, which could significantly contribute to global elimination efforts by reaching difficult-to-engage populations such as homeless individuals, people who inject drugs, and individuals in low- or middle-income settings.